SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: quidditch who wrote (3257)6/8/1999 11:34:00 AM
From: Biomaven  Read Replies (3) of 10280
 
One possibility on Zyrtec is that SEPR is planning on free riding on the European studies. The big prize is of course the US market, and this way someone else gets to do a lot of the work, while SEPR retains all rights to the US market. Having the ICE already approved (or close to approval) in Europe would give them major leverage with PFE. So my speculation is that SEPR was maybe more concerned with getting to use the results of the trials than in jacking up the European royalty.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News